LGC Implements Sensitive Assays to Improve Drug Success
25 Jul 2019
Michael Naughton, Senior Scientist in the Biologicals department within Drug Development Services at LGC, discusses how the company is implementing more sensitive assays to detect low abundance biomarkers and analytes, to meet the needs of the pharmaceutical industry. Hear how the Singulex Erenna® Immunoassay Platform from MilliporeSigma enables sensitive detection of analytes at below endogenous levels, providing a unique insight into health and disease states that can aid early decision making. A case study for IL-6 is presented.
Related Products
Request Quote for All Products
Bioanalysis of peptides service
ResolianOur industry leading bioanalytical solutions have helped our clients develop new peptide therapeutics to improve the quality of life. Combining our experience and cutting-edge technology, we have has developed and validated methods using LC-MS/MS to quantify levels of peptides in plasma at levels as low as 10 pg/mL.
Biopharmaceutical Development Service
ResolianResolian has established itself as a world-class leader in biopharmaceutical drug development through analytical excellence with over 500 scientists across three global labs.
